TABLE I. Characteristics of Patients with Fore-/Midgut Net According to Functional Activity, Site and KI-67 Proliferation Index.

Tumor no.	Diagnosis	Origin	Behavior	Ki-67 (%)	CIMP	MSI (marker)	LOH (marker)	Follow-up time (weeks)	Survival	Gender	Age at diagnosis
8	Insulinoma	Pancreas	Malignant	<2	−	MSS	−	12	tu	m	79
14	Insulinoma	Pancreas	Benign	<2	−	MSS	−	192	Survived	f	52
16	Insulinoma	Pancreas	Benign	<2	+	MSS	−	60	Survived	f	77
19	Insulinoma	Pancreas	Malignant	2–20	−	MSS	+ (D5S346)	12	tu	f	79
12	Gastrinoma	Pancreas	Benign	2–20	−	MSS	na	36	tu	m	81
2	Vipoma	Pancreas	Malignant	2–20	−	MSS	−	60	Survived	m	56
17	Vipoma	Pancreas	Benign	2–20	+	MSS	−	76	Survived	m	56
1	Glucagonoma	Pancreas	Malignant	2–20	−	MSS	−	8	tu	f	50
5	Nonfunctional	Pancreas	Malignant	<2	+	MSS	na	84	Survived	m	61
4	Nonfunctional	Pancreas	Malignant	2–20	−	MSS	na	72	Survived	f	36
28	Nonfunctional	Duodenum	Malignant	<2	+	MSS	−	96	Survived	m	71
34	Nonfunctional	Duodenum	Malignant	<2	−	MSI-L	na	98	Survived	f	81
37	Nonfunctional	Duodenum	Malignant	<2	+	MSS	−	96	Survived	m	70
9	Nonfunctional	Duodenum	Malignant	2–20	−	MSS	na	12	tu	m	78
30	Nonfunctional	Duodenum	Malignant	2–20	−	MSS	na	35	tu	m	70
6	Gastrinoma	Duodenum	Malignant	<2	−	MSI-L	na	10	tu	f	49
15	Gastrinoma	Duodenum	Benign	<2	−	MSS	−	192	Survived	m	48
18	Gastrinoma	Duodenum	Benign	<2	−	MSS	−	50	Survived	f	49
3	Gastrinoma	Duodenum	Benign	2–20	−	MSS	+ (D2S123)	48	Survived	m	66
23	Carcinoid syndrome	Ileum	Malignant	<2	−	MSS	−	84	Survived	m	62
24	Carcinoid syndrome	Ileum	Malignant	<2	+	MSS	−	72	Survived	m	66
25	Carcinoid syndrome	Ileum	Malignant	<2	−	MSS	−	72	Survived	m	70
32	Carcinoid syndrome	Ileum	Malignant	<2	+	MSS	−	120	Survived	m	63
35	Carcinoid syndrome	Ileum	Malignant	<2	+	MSS	−	36	tu	f	56
38	Carcinoid syndrome	Ileum	Malignant	<2	−	MSS	na	144	Survived	f	60
33	Carcinoid syndrome	Jejunum	Malignant	<2	−	MSS	−	120	Survived	m	75
36	Carcinoid syndrome	Jejunum	Malignant	<2	−	MSS	na	60	Survived	m	69
13	Nonfunctional	Ileum	Malignant	<2	+	MSS	−	36	tu	f	81
21	Nonfunctional	Ileum	Malignant	<2	−	MSS	na	84	Survived	f	61
22	Nonfunctional	Ileum	Malignant	<2	+	MSS	na	84	Survived	f	61
20	Nonfunctional	Ileum	Malignant	2–20	+	MSS	+ (D17S250)	36	tu	m	66
29	Nonfunctional	Ileum	Malignant	2–20	−	MSI-L	na	35	tu	f	38
31	Nonfunctional	Ileum	Malignant	2–20	−	MSS	+ (D17S250)	24	tu	m	70
10	Nonfunctional	Jejunum	Malignant	<2	−	MSS	na	12	tu	m	71
26	Nonfunctional	Jejunum	Malignant	<2	−	MSS	−	84	Survived	f	49
27	Nonfunctional	Jejunum	Malignant	<2	+	MSS	−	120	Survived	m	51
7	Nonfunctional	Jejunum	Malignant	2–20	−	MSS	−	10	tu	m	65
11	Nonfunctional	Jejunum	Malignant	2–20	−	MSI-L	na	12	tu	f	38

na, not available; tu, died from the tumor; f, female; m, male.